Life Science

The healthcare sector is one of the highest-valued industries in the German M&A market. EBITDA multiples of 7x to 10x are not exceptional for high-quality assets — driven by demographic change, regulatory pressure and structurally growing demand that is independent of economic cycles. Three buyer profiles are particularly active: specialised private equity firms building healthcare platforms in niche segments; strategic consolidators — laboratory groups, care holding companies and medical technology groups — expanding their market position through targeted acquisitions; and international buyers who view access to the German healthcare market as a strategic priority. What makes the difference in valuation: regulatory compliance, billing quality and operational independence from the owner. Those who structure these aspects before a sale typically achieve significantly better terms. How the market currently views your business — we are happy to discuss this confidentially.

The healthcare sector is one of Germany's most active M&A markets. Demographic change, skilled labour shortages and digitalisation pressure are driving sustained consolidation — from medical practices to care service providers and medical technology companies. Strategic investors and specialised private equity firms are actively building platforms and continue to pay attractive multiples for high-quality assets. At the same time, regulatory requirements are increasing, raising the preparation effort before a sale. How the market currently values your business and which buyers are specifically active — we are happy to discuss this confidentially.